Today: 21 May 2026
Kenvue stock edges higher as Kimberly-Clark profit beat puts takeover vote back in play
27 January 2026
1 min read

Kenvue stock edges higher as Kimberly-Clark profit beat puts takeover vote back in play

New York, Jan 27, 2026, 10:52 EST — Regular session

Shares of Kenvue Inc (KVUE) edged up 0.2% to $17.68 in early Tuesday trading, following a quarterly profit beat from potential acquirer Kimberly-Clark (KMB). Kimberly-Clark also reaffirmed its focus on expanding in consumer health. The company’s shares gained 0.7%, reaching $101.89.

The move is crucial given the tight timeline. Shareholders will vote on Kimberly-Clark’s $40 billion bid for Kenvue on Jan. 29, following ISS’s recommendation to back the deal earlier this month.

Kenvue shareholders will get $3.50 in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share, the companies confirmed at the deal’s announcement. The transaction, subject to shareholder and regulatory sign-off, is slated to close in the second half of 2026. Kimberly-Clark has secured financing and plans to cover the cash portion with existing cash, new debt, and proceeds from its upcoming International Family Care and Professional business deal.

That situation has pushed Kenvue into merger arbitrage territory — investors snap up the target and sometimes hedge the acquirer, betting on the difference between the offer price and the trading price of the target. When that spread widens, it typically signals the market is factoring in higher risks of the deal faltering, shrinking, or falling through.

Kimberly-Clark CEO Mike Hsu described the Kenvue deal on Tuesday as “a powerful next step” in the company’s ongoing transformation, adding that integration planning is underway. The company also noted that funds from its IFP transaction are intended to support the acquisition. PR Newswire

Shareholder meetings are set for Thursday morning and will take place virtually. Voting instructions must be submitted before the session, according to a proxy filing.

Deal risk remains a factor. Kenvue has been hit with lawsuits and regulatory scrutiny over legacy products, sparking debate among investors about the impact of these liabilities on the merged entity — and if they might delay the timeline.

Thursday’s vote is the immediate focus for investors. Once that’s settled, the spotlight will turn to fresh updates on litigation, financing structure, and how quickly regulators are moving — the key factors that will determine if Kenvue stays in deal mode or reverts to trading on its core fundamentals.

Stock Market Today

  • SpaceX IPO Filing Reveals Financials, Musk Could Become First Trillionaire
    May 20, 2026, 7:08 PM EDT. SpaceX filed for an initial public offering (IPO), disclosing its finances and board members for the first time. The company reported $18.7 billion in revenue for 2025, up 33% year-on-year, but posted a net loss of $4.9 billion, reversing a $791 million profit in 2024. First-quarter 2026 losses reached $4.3 billion on $4.7 billion revenue. The IPO, trading as SPCX, may become the largest ever, potentially boosting Elon Musk's wealth to trillionaire status. SpaceX aims to fund its ambitious plans including Starlink satellite network expansion, AI infrastructure, and establishing extraterrestrial colonies.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps
Previous Story

Dow Jones drops 450 points as UnitedHealth sinks on Medicare rates; confidence slumps

Lumen Technologies (LUMN) stock jumps on ISO 42001 AI certification as earnings loom
Next Story

Lumen Technologies (LUMN) stock jumps on ISO 42001 AI certification as earnings loom

Go toTop